The global peptic ulcer drugs market size reached US$ 4.8 Billion in 2023. Looking forward, the market is projected to reach US$ 6.1 Billion by 2032, exhibiting a growth rate (CAGR) of 2.70% during 2023-2032. The increasing prevalence of peptic ulcers, especially amongst the geriatric population and shifting consumer inclination toward various medications over invasive surgeries represent some of the key factors driving the market.
Peptic ulcers, or duodenal ulcers, are open sore that gradually develops and triggers defects in the lining of the stomach, small intestine, and lower esophagus. They are usually caused due to inflammation, radiation therapy, frequent oral and injectable administration of aspirins, and anti-inflammatory drugs. If peptic ulcers are left untreated, they might initiate severe pain in the mid- or upper-body parts, weight loss, internal bleeding, and severe blood loss, which require hospitalization. Currently, they can be treated with various drug types, including proton pump inhibitors (PPI), H2 antagonists, antibiotics, potassium-competitive acid blockers (P-CAB), antacids, and ulcer protectives.
These medications reduce body aches, provide more time to heal, minimize acid secretion, offer resistance against bacterial infections, and protect the stomach from digestive juices. As a result, peptic ulcer drugs are extensively utilized by healthcare practitioners for the treatment of gastritis, gastroesophageal reflux disease (GERD), and duodenal ulcers.
Additionally, the ongoing approvals of peptic ulcer drugs and several government investments in pharmaceutical companies for the formulation of medications are supporting the market growth. This is further influenced by the continuous conduction of clinical trials for new drug formation to overcome complications and the ineffectiveness of present drugs in the market. Moreover, the increasing consumer awareness regarding the benefits of cost-effective peptic ulcer drugs and their easy availability across multiple distribution channels is favoring the market growth.
The advent of artificial intelligence (AI)-based pathology testing technology to perform diagnostic and forensic operations is also propelling the market growth. Other factors, such as extensive research and development (R&D) activities to enhance product efficacy and the increasing investments in the development of the over the counter (OTC) medications for treating peptic ulcers, are positively impacting the market growth.
Some of the factors driving the North America peptic ulcer drugs market included the increasing prevalence of peptic ulcers, especially amongst the geriatric population and shifting consumer inclination toward various peptic ulcer curing drugs over invasive surgeries and the fueling need for over-the-counter (OTC) medications in the healthcare sector.
Peptic ulcers, or duodenal ulcers, are open sore that gradually develops and triggers defects in the lining of the stomach, small intestine, and lower esophagus. They are usually caused due to inflammation, radiation therapy, frequent oral and injectable administration of aspirins, and anti-inflammatory drugs. If peptic ulcers are left untreated, they might initiate severe pain in the mid- or upper-body parts, weight loss, internal bleeding, and severe blood loss, which require hospitalization. Currently, they can be treated with various drug types, including proton pump inhibitors (PPI), H2 antagonists, antibiotics, potassium-competitive acid blockers (P-CAB), antacids, and ulcer protectives.
These medications reduce body aches, provide more time to heal, minimize acid secretion, offer resistance against bacterial infections, and protect the stomach from digestive juices. As a result, peptic ulcer drugs are extensively utilized by healthcare practitioners for the treatment of gastritis, gastroesophageal reflux disease (GERD), and duodenal ulcers.
Peptic Ulcer Drugs Market Trends
The increasing prevalence of peptic ulcers, especially amongst the geriatric population, represents one of the key factors driving the market growth. Moreover, unhealthy lifestyle habits and rising instances of stomach cancer, is resulting in the growing number of individuals suffering from peptic ulcers. This, along with the shifting consumer inclination towards various peptic ulcer-curing drugs over invasive surgeries, which, in turn, is contributing to the market growth. In line with this, as compared to surgical procedures, several steroidal anti-inflammatory medications are minimally invasive, more affordable, and enable faster recovery while ensuring reduced blood loss.Additionally, the ongoing approvals of peptic ulcer drugs and several government investments in pharmaceutical companies for the formulation of medications are supporting the market growth. This is further influenced by the continuous conduction of clinical trials for new drug formation to overcome complications and the ineffectiveness of present drugs in the market. Moreover, the increasing consumer awareness regarding the benefits of cost-effective peptic ulcer drugs and their easy availability across multiple distribution channels is favoring the market growth.
The advent of artificial intelligence (AI)-based pathology testing technology to perform diagnostic and forensic operations is also propelling the market growth. Other factors, such as extensive research and development (R&D) activities to enhance product efficacy and the increasing investments in the development of the over the counter (OTC) medications for treating peptic ulcers, are positively impacting the market growth.
Key Market Segmentation
This report provides an analysis of the key trends in each segment of the global peptic ulcer drugs market, along with forecasts at the global, regional, and country level from 2024-2032. The report has categorized the market based on product type, ulcer type, and distribution channel.Product Type Insights:
- Proton Pump Inhibitors
- Potassium-Competitive Acid Blocker (P-CAB)
- Antacids
- H2-Antagonists
- Antibiotics
- Ulcer protective
Ulcer Type Insights:
- Gastric Ulcer
- Duodenal Ulcer
- Others
Distribution Channel Insights:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Regional Insights:
- North America
- United States
- Canada
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
Some of the factors driving the North America peptic ulcer drugs market included the increasing prevalence of peptic ulcers, especially amongst the geriatric population and shifting consumer inclination toward various peptic ulcer curing drugs over invasive surgeries and the fueling need for over-the-counter (OTC) medications in the healthcare sector.
Competitive Landscape
The report has also provided a comprehensive analysis of the competitive landscape in the global peptic ulcer drugs market. Detailed profiles of all major companies have also been provided. Some of the companies covered include Abbott Laboratories, AstraZeneca plc, Boehringer Ingelheim International GmbH, Novitium Pharma LLC, Pfizer Inc., PharmaKing Co. Ltd., RedHill Biopharma Ltd, Viatris Inc., Yuhan Corporation, Zydus Lifesciences Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.Key Questions Answered in This Report
- How has the global peptic ulcer drugs market performed so far and how will it perform in the coming years?
- What are the drivers, restraints, and opportunities in the global peptic ulcer drugs market?
- What are the key regional markets?
- Which countries represent the most attractive peptic ulcer drug markets?
- What is the breakup of the market based on the product type?
- What is the breakup of the market based on the ulcer type?
- What is the breakup of the market based on the distribution channel?
- What is the competitive structure of the global peptic ulcer drugs market?
- Who are the key players/companies in the global peptic ulcer drugs market?
Table of Contents
1 Preface3 Executive Summary11 Value Chain Analysis13 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global Peptic Ulcer Drugs Market
6 Market Breakup by Product Type
7 Market Breakup by Ulcer Type
8 Market Breakup by Distribution Channel
9 Market Breakup by Region
10 Drivers, Restraints, and Opportunities
12 Porters Five Forces Analysis
14 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Abbott Laboratories
- AstraZeneca plc
- Boehringer Ingelheim International GmbH
- Novitium Pharma LLC
- Pfizer Inc.
- PharmaKing Co. Ltd.
- RedHill Biopharma Ltd
- Viatris Inc.
- Yuhan Corporation
- Zydus Lifesciences Limited
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 137 |
| Published | April 2024 |
| Forecast Period | 2023 - 2032 |
| Estimated Market Value ( USD | $ 4.8 Billion |
| Forecasted Market Value ( USD | $ 6.1 Billion |
| Compound Annual Growth Rate | 2.7% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
